Search the Community
Showing results for tags 'tracleer'.
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and digital ulcer-related symptoms. PubMed, Exp Ther Med, 2020 Mar;19(3):1739-1746. (Also see Tracleer (Bosentan)) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.